Equities

Mustang Bio Inc

MBIO:NAQ

Mustang Bio Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)0.222
  • Today's Change-0.001 / -0.45%
  • Shares traded736.34k
  • 1 Year change-90.75%
  • Beta1.9616
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments6.2376110
Total Receivables, Net3.880.040.05
Total Inventory------
Prepaid expenses1.233.162.04
Other current assets, total------
Total current assets1179112
Property, plant & equipment, net4.811212
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets0.830.260.36
Total assets1892125
LIABILITIES
Accounts payable6.326.833.51
Accrued expenses8.317.636.75
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total0.740.650.55
Total current liabilities151511
Total long term debt0270
Total debt0270
Deferred income tax------
Minority interest------
Other liabilities, total2.253.601.96
Total liabilities184613
SHAREHOLDERS EQUITY
Common stock0.591.124.34
Additional paid-in capital381375360
Retained earnings (accumulated deficit)(381)(329)(252)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total----0.00
Total equity0.1246112
Total liabilities & shareholders' equity1892125
Total common shares outstanding9.648.137.25
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.